Nonalcoholic fatty liver disease (NAFLD) is a condition which causes fat to accumulate in the liver. Nonalcoholic steatohepatitis (NASH) is a severe form of the disease in which the patient also…
According to a story from Scleroderma News, a recent study found that men were more likely to have severe scleroderma early in their diagnosis in comparison to women. This is…
According to a story from the Dartmouth Geisel School of Medicine, a group of researchers associated with the school recently published a study that indicated that certain scleroderma patients that…
New data has been released about the effects of lenabasum, an experimental drug, on patients with systemic sclerosis and dermatomyositis. Corbus, who are developing lenabasum, are planning to present…
According to a story from Scleroderma News, the results from a recent study suggest that the six minute walk test can accurately predict outcomes for patients with systemic sclerosis. A…
An open-label extension of a Phase II study has shown that the experimental drug lenabasum is fairly safe and tolerable in patients who have diffuse cutaneous systemic sclerosis. The full…
A recently published study has found that a protein the in blood, called CC16, can predict lung disease progression in patients with systemic sclerosis. High levels of the protein are…
Research into graft-versus-host-disease (GVHD), a condition that can occur after bone marrow transplants, has yielded promising results. A study, reported by BrightSurf, found that a particular group of microRNA molecules involved…
Patients with a form of scleroderma called systemic sclerosis are particularly susceptible to developing high blood pressure in their heart and lungs, also known as pulmonary hypertension. A new study…
According to a story from BioSpace, the U.S. Food and Drug Administration has given Fast Track designation for nintedanib, which is undergoing testing for the treatment of systemic sclerosis with…
© Copyright Patient Worthy
